Journal ArticleDOI
Pharmacological aspects of the neuroprotective effects of irreversible MAO-B inhibitors, selegiline and rasagiline, in Parkinson’s disease
TLDR
The era of MAO-B inhibitors dates back more than 50 years and began with Kálmán Magyar’s outstanding discovery of the selective inhibitor, selegiline, which is still regarded as the gold standard, although newer drugs have also been introduced to the field.Abstract:
The era of MAO-B inhibitors dates back more than 50 years It began with Kalman Magyar’s outstanding discovery of the selective inhibitor, selegiline This compound is still regarded as the gold standard of MAO-B inhibition, although newer drugs have also been introduced to the field It was revealed early on that selective, even irreversible inhibition of MAO-B is free from the severe side effect of the non-selective MAO inhibitors, the potentiation of tyramine, resulting in the so-called ‘cheese effect’ Since MAO-B is involved mainly in the degradation of dopamine, the inhibitors lack any antidepressant effect; however, they became first-line medications for the therapy of Parkinson’s disease based on their dopamine-sparing activity Extensive studies with selegiline indicated its complex pharmacological activity profile with MAO-B-independent mechanisms involved Some of these beneficial effects, such as neuroprotective and antiapoptotic properties, were connected to its propargylamine structure The second MAO-B inhibitor approved for the treatment of Parkinson’s disease, rasagiline also possesses this structural element and shows similar pharmacological characteristics The preclinical studies performed with selegiline and rasagiline are summarized in this reviewread more
Citations
More filters
Journal ArticleDOI
Is It Reliable to Take the Molecular Docking Top Scoring Position as the Best Solution without Considering Available Structural Data
David Ramírez,Julio Caballero +1 more
TL;DR: It is found that docking score function is capable of predicting crystallographic binding orientations, but the best ranked solution according to the docking energy is not always the pose that reproduces the experimental binding orientation.
Journal ArticleDOI
Monoamine oxidase inhibitors, and iron chelators in depressive illness and neurodegenerative diseases
TL;DR: Recent novel therapeutic drugs for neurodegenerative diseases has led to the development of multi target drugs, that possess selective brain MAO A and B inhibitory moiety, iron chelating and antioxidant activities and the ability to increase brain levels of endogenous neurotrophins.
Journal ArticleDOI
Inhibitors of MAO-B and COMT: their effects on brain dopamine levels and uses in Parkinson's disease.
TL;DR: The scientific background to the localization and function of the enzymes, the physiological changes resulting from their inhibition, and the basic and clinical pharmacology of the various inhibitors and their role in treatment of Parkinson’s disease are described.
Journal ArticleDOI
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
Peter Riederer,Thomas Müller +1 more
TL;DR: The symptomatic effects of MAO-B inhibition for a limited amelioration of impaired motor behaviour and wearing-off phenomena in patients with Parkinson’s disease are well proven, even when MAo-B inhibitors are only applied together with dopamine agonists.
Journal ArticleDOI
Selegiline: a molecule with innovative potential
TL;DR: Cell and molecular studies revealed interesting properties of selegiline opening new possibilities for neuroprotective mechanisms and a disease-modifying effect of MAO-B inhibitors.
References
More filters
Journal ArticleDOI
Mitochondrial complex I deficiency in Parkinson's disease.
TL;DR: Results indicated a specific defect of Complex I activity in the substantia nigra of patients with Parkinson's disease, which adds further support to the proposition that Parkinson’s disease may be due to an environmental toxin with action(s) similar to those of MPTP.
Journal ArticleDOI
Some observations upon a new inhibitor of monoamine oxidase in brain tissue.
TL;DR: The hypothesis that in the enzyme prepared, the MAO is a binary system of enzymes each of which has a detectably different sensitivity to this particular inhibitor, is put forward and evidence after dialysis supports this hypothesis.
Journal ArticleDOI
Mitochondrial complex I deficiency in Parkinson's disease.
Journal ArticleDOI
Chronic Parkinsonism secondary to intravenous injection of meperidine analogues.
Glenn C. Davis,Adrian C. Williams,Sanford P. Markey,Michael H. Ebert,Eric D. Caine,Cheryl M. Reichert,Irwin J. Kopin +6 more
TL;DR: Biogenic amines and metabolites in the cerebrospinal fluid and microscopic evaluation of the brain at necropsy were consistent with damage to aminergic neurons in the substantia nigra.
Journal ArticleDOI
Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenyl-pyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine
TL;DR: Compromise of mitochondrial oxidative capacity by MPP+ could be an important factor in mechanisms underlying the toxicity of MPTP.
Related Papers (5)
The therapeutic potential of monoamine oxidase inhibitors.
Monoamine oxidase-B inhibitors in the treatment of Parkinson's disease: clinical-pharmacological aspects.
Peter Riederer,Thomas Müller +1 more